Sitaphol MXR Sustained-Release Tablets 100/1000 mg

Adult dose

Take one sustained-release tablet (100/1000 mg) once daily. Patients taking the 50/500 mg or 50/1000 mg sustained-release tablets should take two tablets simultaneously once daily. 1. Patients not currently treated with metformin: The initial dosage is a total daily amount of 100 mg sitagliptin and 1000 mg metformin. Sufficient blood sugar control should be achieved.

This medication is a combination drug containing sitagliptin and metformin, primarily used for blood sugar control in patients with type 2 diabetes. Serious allergic reactions may occur during treatment, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck arise, discontinue use immediately and consult a physician. There is a risk of pancreatitis, which is inflammation of the pancreas, so symptoms like abdominal pain, vomiting, or persistent nausea should be reported to healthcare professionals immediately. The metformin component of this drug can rarely cause lactic acidosis, a serious metabolic disorder that is very dangerous; symptoms like muscle pain, lethargy, difficulty breathing, or abdominal pain require immediate medical attention. Patients with poor kidney function or those experiencing severe infections, dehydration, or heart issues may be at risk when using this medication, so it is essential to inform the physician if any such conditions are present. This medication should especially not be used in cases of moderate to severe renal impairment or acute heart failure, acute myocardial infarction, or sepsis. Before and after tests involving iodine contrast agents, this medication should be temporarily discontinued due to the risk of worsened kidney function and lactic acidosis, and should be resumed only after confirming normal kidney function post-examination. It is safer for pregnant or potentially pregnant women, as well as nursing mothers, to avoid using this medication. During treatment, irregular meals, excessive exercise, and interactions with other medications can lead to a risk of hypoglycemia, so caution is advised. When taken alongside sulfonylureas or insulin, hypoglycemic symptoms may appear, requiring frequent blood sugar monitoring and potential dosage adjustments after consulting a physician. Additionally, patients with impaired liver function or those who consume alcohol excessively should consult a physician before using this medication due to an increased risk of lactic acidosis. Regular kidney function and blood tests should be conducted during treatment, as vitamin B12 levels may decrease, necessitating periodic testing. Before surgery, discontinue use 48 hours prior, and resume only after confirming normal kidney function and oral intake post-surgery. It is crucial to inform healthcare professionals of any unusual symptoms or discomfort experienced during the use of this medication.

Serious side effects

Hives, severe swelling (angioedema), anaphylaxis, rash, exfoliative skin diseases (including Stevens-Johnson syndrome), acute pancreatitis, acute renal failure, bullous pemphigoid, elevated liver enzymes, liver abnormalities (including jaundice), severe allergic reactions, lactic acidosis, severe edema, high blood pressure, severe headache, seizures, altered consciousness, visual disturbances, paralysis, difficulty breathing, asthma attacks, thrombocytopenia, rhabdomyolysis

Mild side effects

• Upper respiratory infection
• nasopharyngitis
• diarrhea
• nausea
• vomiting
• abdominal pain
• headache
• myalgia
• limb pain
• back pain

This medication should be stored in a tightly sealed container to protect it from air and moisture, with a recommended storage temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy and safety of the drug over time.

Appearance

Bright blue, oval-shaped, biconvex sustained-release film-coated tablets

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle